Financial Engines Advisors L.L.C. bought a new position in Grifols, S.A. (NASDAQ:GRFS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 48,136 shares of the biotechnology company's stock, valued at approximately $358,000.
Other large investors have also recently made changes to their positions in the company. R Squared Ltd purchased a new stake in Grifols in the fourth quarter worth about $28,000. GAMMA Investing LLC grew its stake in shares of Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock worth $37,000 after buying an additional 1,527 shares during the last quarter. Blue Trust Inc. increased its position in Grifols by 254.0% during the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock valued at $52,000 after buying an additional 4,970 shares in the last quarter. Envestnet Portfolio Solutions Inc. purchased a new position in Grifols during the fourth quarter valued at $77,000. Finally, Raymond James Financial Inc. bought a new stake in Grifols in the fourth quarter worth $91,000.
Grifols Stock Performance
Shares of NASDAQ GRFS traded down $0.15 during midday trading on Tuesday, hitting $6.96. 1,236,688 shares of the stock traded hands, compared to its average volume of 1,234,149. The firm has a 50-day moving average of $7.55 and a two-hundred day moving average of $8.01. The firm has a market capitalization of $4.79 billion, a P/E ratio of 5.95 and a beta of 0.35. Grifols, S.A. has a one year low of $5.79 and a one year high of $9.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.
Wall Street Analyst Weigh In
Separately, Morgan Stanley started coverage on shares of Grifols in a research note on Wednesday, February 12th. They set an "overweight" rating for the company.
Check Out Our Latest Research Report on GRFS
Grifols Profile
(
Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Featured Articles
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
